TBK1 and breast carcinoma: By inhibiting RB1CC1, AZI2 accumulates, leading to overactivation of TBK1-IFN, promotion of cytokine expression in breast cancer, CD8T cell infiltration, and improvement of the response of breast cancer to ICI (84).